Importantly, partial BACE1+/− reduction and lower-dose BACE1 inhibitors are, however, devoid of such mechanism-based side effects (Ohno, 2016; Zhu et al., 2018b), supporting the promise of a rational, low-dose approach initiated at the earliest preclinical stage of AD. The gene discussed is BACE1; the disease is Alzheimer disease.